These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15553395)

  • 1. FDA and the life-sciences industry: business as usual?
    Koski G
    Hastings Cent Rep; 2004; 34(5):24-7. PubMed ID: 15553395
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA and the life-sciences industry: business as usual?".
    Rein BW
    Hastings Cent Rep; 2005; 35(2):7; author reply 7. PubMed ID: 15957308
    [No Abstract]   [Full Text] [Related]  

  • 3. Congress may force drug firms to reveal clinical trial data.
    Check E
    Nature; 2004 Sep; 431(7006):232. PubMed ID: 15371992
    [No Abstract]   [Full Text] [Related]  

  • 4. Conflict of interest in industry-sponsored drug development.
    Emanuel EJ
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):265-7. PubMed ID: 17607285
    [No Abstract]   [Full Text] [Related]  

  • 5. Calls for full disclosure of clinical trials.
    Frantz S
    Nat Rev Drug Discov; 2004 Aug; 3(8):635-6. PubMed ID: 15317144
    [No Abstract]   [Full Text] [Related]  

  • 6. Must an interest be a conflict?
    Lyles A
    Clin Ther; 2005 Mar; 27(3):344-5. PubMed ID: 15878388
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to 'Truth in numbers'.
    Kim PS
    Nat Med; 2006 Mar; 12(3):269. PubMed ID: 16520764
    [No Abstract]   [Full Text] [Related]  

  • 8. Paroxetine and the FDA.
    Brent DA
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):127-8. PubMed ID: 14971062
    [No Abstract]   [Full Text] [Related]  

  • 9. A disclosure dilemma: what you don't know can kill you, but so can what you do know.
    von Biela LM
    Food Drug Law J; 2010; 65(2):317-46, ii. PubMed ID: 24475544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 11. Summer recess might squeeze FDA reform bill.
    Fox JL
    Nat Biotechnol; 1997 Aug; 15(8):715. PubMed ID: 9333520
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 13. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P
    MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trial protocols: agreements between the FDA and industrial sponsors.
    Mann H
    Lancet; 2002 Nov; 360(9343):1345-6. PubMed ID: 12423978
    [No Abstract]   [Full Text] [Related]  

  • 15. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
    Dorfman HL; Reig LP
    Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
    [No Abstract]   [Full Text] [Related]  

  • 16. Transparent reaction. Suppliers oppose FDA move to disclose more data.
    Rhea S
    Mod Healthc; 2010 Jul; 40(30):16. PubMed ID: 20695055
    [No Abstract]   [Full Text] [Related]  

  • 17. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA, Juno Therapeutics, and the ethical imperative of transparency.
    Hey SP; Kesselheim AS
    BMJ; 2016 Aug; 354():i4435. PubMed ID: 27526698
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA to review "missing" drug company documents.
    Lenzer J
    BMJ; 2005 Jan; 330(7481):7. PubMed ID: 15626785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.